VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to developing novel therapies for anxiety, depression, and other central nervous system disorders. The company's leading candidate, AV-101, targets significant unmet needs in mental health, showcasing its commitment to advancing innovative neuropharmacological treatments. With a robust pipeline and strategic focus on CNS therapeutics, VistaGen offers a promising opportunity for institutional investors interested in impactful healthcare innovations. Show more

Location: 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA | Website: https://www.vistagen.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

22.05M

52 Wk Range

$0.54 - $5.14

Previous Close

$0.56

Open

$0.56

Volume

525,911

Day Range

$0.56 - $0.60

Enterprise Value

-53.26M

Cash

62.79M

Avg Qtr Burn

-13.76M

Insider Ownership

0.27%

Institutional Own.

58.27%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Fasedienol (PH94B) Details Social Anxiety Disorder	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PH80 (nasal spray) Details Menopause, Hot flashes	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Itruvone, PH10 (pherine nasal spray ) Details Major depressive disorder	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PH15 (pherine nasal spray) Details Cognitive Dysfunction	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PH284 (nasal spray) Details Cancer cachexia	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fasedienol (PH94B) (pherine nasal spray) Details Adjustment Disorder	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AV-101(4-Cl-KYN) (targets the NMDAR) Details Major depressive disorder	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.